Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Inhibikase Therapeutics Inc
(NQ:
IKT
)
1.430
+0.060 (+4.38%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Inhibikase Therapeutics Inc
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
August 14, 2024
Company to host conference call on August 15, 2024 at 8:00 a.m. ET
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
August 07, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
June 17, 2024
Company expects to report trial results in 4Q24
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
June 05, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
May 20, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
May 15, 2024
Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
May 15, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
May 09, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
April 18, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
April 03, 2024
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
March 27, 2024
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
March 07, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
February 28, 2024
Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
February 07, 2024
- The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson’s disease -
From
Inhibikase Therapeutics
Via
GlobeNewswire
Dr. Milton Werner, CEO of Inhibikase Therapeutics, Inc. is Featured in an Interview With SmallCapsDaily
February 05, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
January 29, 2024
Via
AB Newswire
Topics
Retirement
Exposures
Pension
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
January 29, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
January 16, 2024
Joseph Frattaroli to retire at end of 1Q24; Garth Lees-Rolfe, Vice-President of Finance, to be promoted to Chief Financial Officer
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
December 19, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
December 04, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
November 14, 2023
Company to host conference call on Wednesday, November 15, 2023 at 8:00 a.m. ET
From
Inhibikase Therapeutics
Via
GlobeNewswire
Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023
November 07, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023
November 07, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment
October 16, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy
October 04, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Shares Of Inhibikase Therapeutics Stock Decouples From NASDAQ Weakness; Jump 8% Including A/H Wednesday As Interest In Ikt-148009 Intensifies ($IKT)
March 16, 2023
Via
AB Newswire
Exposures
Product Safety
Inhibikase Therapeutics Stock Turns Bullish After FDA Lifts Full Clinical Hold For Lead Candidate IkT-148009 ($IKT)
March 14, 2023
Via
AB Newswire
Exposures
Product Safety
NASDAQ Co. Working Towards Advanced Treatments for Parkinson’s Disease and Cancer. Inhibikase Therapeutics (NASDAQ: IKT)
June 07, 2021
NASDAQ Company Diligently Working Towards Advanced Treatments for Parkinson’s Disease and Cancer: Inhibikase Therapeutics, Inc. (Stock Symbol: IKT)
Via
EIN Presswire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.